Literature DB >> 22298777

Characterization of heparin-binding site of tissue transglutaminase: its importance in cell surface targeting, matrix deposition, and cell signaling.

Zhuo Wang1, Russell J Collighan, Kamila Pytel, Daniel L Rathbone, Xiaoling Li, Martin Griffin.   

Abstract

Tissue transglutaminase (TG2) is a multifunctional Ca(2+)-activated protein cross-linking enzyme secreted into the extracellular matrix (ECM), where it is involved in wound healing and scarring, tissue fibrosis, celiac disease, and metastatic cancer. Extracellular TG2 can also facilitate cell adhesion important in wound healing through a nontransamidating mechanism via its association with fibronectin, heparan sulfates (HS), and integrins. Regulating the mechanism how TG2 is translocated into the ECM therefore provides a strategy for modulating these physiological and pathological functions of the enzyme. Here, through molecular modeling and mutagenesis, we have identified the HS-binding site of TG2 (202)KFLKNAGRDCSRRSSPVYVGR(222). We demonstrate the requirement of this binding site for translocation of TG2 into the ECM through a mechanism involving cell surface shedding of HS. By synthesizing a peptide NPKFLKNAGRDCSRRSS corresponding to the HS-binding site within TG2, we also demonstrate how this mimicking peptide can in isolation compensate for the RGD-induced loss of cell adhesion on fibronectin via binding to syndecan-4, leading to activation of PKCα, pFAK-397, and ERK1/2 and the subsequent formation of focal adhesions and actin cytoskeleton organization. A novel regulatory mechanism for TG2 translocation into the extracellular compartment that depends upon TG2 conformation and the binding of HS is proposed.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22298777      PMCID: PMC3339925          DOI: 10.1074/jbc.M111.294819

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  44 in total

1.  RGD-independent cell adhesion via a tissue transglutaminase-fibronectin matrix promotes fibronectin fibril deposition and requires syndecan-4/2 α5β1 integrin co-signaling.

Authors:  Zhuo Wang; Russell J Collighan; Stephane R Gross; Erik H J Danen; Gertraud Orend; Dilek Telci; Martin Griffin
Journal:  J Biol Chem       Date:  2010-10-07       Impact factor: 5.157

Review 2.  Proteoglycans in health and disease: the multiple roles of syndecan shedding.

Authors:  Tina Manon-Jensen; Yoshifumi Itoh; John R Couchman
Journal:  FEBS J       Date:  2010-08-31       Impact factor: 5.542

3.  Importance of syndecan-4 and syndecan -2 in osteoblast cell adhesion and survival mediated by a tissue transglutaminase-fibronectin complex.

Authors:  Z Wang; D Telci; M Griffin
Journal:  Exp Cell Res       Date:  2010-10-28       Impact factor: 3.905

4.  Redox regulation of transglutaminase 2 activity.

Authors:  Jorunn Stamnaes; Daniel M Pinkas; Burkhard Fleckenstein; Chaitan Khosla; Ludvig M Sollid
Journal:  J Biol Chem       Date:  2010-06-14       Impact factor: 5.157

5.  SST0001, a chemically modified heparin, inhibits myeloma growth and angiogenesis via disruption of the heparanase/syndecan-1 axis.

Authors:  Joseph P Ritchie; Vishnu C Ramani; Yongsheng Ren; Annamaria Naggi; Giangiacomo Torri; Benito Casu; Sergio Penco; Claudio Pisano; Paolo Carminati; Monica Tortoreto; Franco Zunino; Israel Vlodavsky; Ralph D Sanderson; Yang Yang
Journal:  Clin Cancer Res       Date:  2011-01-21       Impact factor: 12.531

6.  Structural basis for the guanine nucleotide-binding activity of tissue transglutaminase and its regulation of transamidation activity.

Authors:  Shenping Liu; Richard A Cerione; Jon Clardy
Journal:  Proc Natl Acad Sci U S A       Date:  2002-02-26       Impact factor: 11.205

7.  The shedding of syndecan-4 and syndecan-1 from HeLa cells and human primary macrophages is accelerated by SDF-1/CXCL12 and mediated by the matrix metalloproteinase-9.

Authors:  Severine Brule; Nathalie Charnaux; Angela Sutton; Dominique Ledoux; Thomas Chaigneau; Line Saffar; Liliane Gattegno
Journal:  Glycobiology       Date:  2006-03-02       Impact factor: 4.313

8.  Unconventional secretion of tissue transglutaminase involves phospholipid-dependent delivery into recycling endosomes.

Authors:  Evgeny A Zemskov; Irina Mikhailenko; Ru-Ching Hsia; Liubov Zaritskaya; Alexey M Belkin
Journal:  PLoS One       Date:  2011-04-27       Impact factor: 3.240

9.  Tissue transglutaminase is an integrin-binding adhesion coreceptor for fibronectin.

Authors:  S S Akimov; D Krylov; L F Fleischman; A M Belkin
Journal:  J Cell Biol       Date:  2000-02-21       Impact factor: 10.539

10.  Shedding of syndecan-1 and -4 ectodomains is regulated by multiple signaling pathways and mediated by a TIMP-3-sensitive metalloproteinase.

Authors:  M L Fitzgerald; Z Wang; P W Park; G Murphy; M Bernfield
Journal:  J Cell Biol       Date:  2000-02-21       Impact factor: 10.539

View more
  31 in total

1.  Celiac disease patient IgA antibodies induce endothelial adhesion and cell polarization defects via extracellular transglutaminase 2.

Authors:  Cristina Antonella Nadalutti; Ilma Rita Korponay-Szabo; Katri Kaukinen; Martin Griffin; Markku Mäki; Katri Lindfors
Journal:  Cell Mol Life Sci       Date:  2013-08-28       Impact factor: 9.261

2.  Inhibition or ablation of transglutaminase 2 impairs astrocyte migration.

Authors:  Alina Monteagudo; Changyi Ji; Abdullah Akbar; Jeffrey W Keillor; Gail V W Johnson
Journal:  Biochem Biophys Res Commun       Date:  2016-11-27       Impact factor: 3.575

3.  Syndecan-4 knockout leads to reduced extracellular transglutaminase-2 and protects against tubulointerstitial fibrosis.

Authors:  Alessandra Scarpellini; Linghong Huang; Izhar Burhan; Nina Schroeder; Muriel Funck; Timothy S Johnson; Elisabetta A M Verderio
Journal:  J Am Soc Nephrol       Date:  2013-12-19       Impact factor: 10.121

Review 4.  Role of transglutaminase 2 in celiac disease pathogenesis.

Authors:  Cornelius Klöck; Thomas R Diraimondo; Chaitan Khosla
Journal:  Semin Immunopathol       Date:  2012-03-22       Impact factor: 9.623

Review 5.  Factor XIIIa inhibitors as potential novel drugs for venous thromboembolism.

Authors:  Rami A Al-Horani; Srabani Kar
Journal:  Eur J Med Chem       Date:  2020-05-18       Impact factor: 6.514

Review 6.  Physiological, pathological, and structural implications of non-enzymatic protein-protein interactions of the multifunctional human transglutaminase 2.

Authors:  Kajal Kanchan; Mónika Fuxreiter; László Fésüs
Journal:  Cell Mol Life Sci       Date:  2015-05-06       Impact factor: 9.261

Review 7.  Regulation of the activities of the mammalian transglutaminase family of enzymes.

Authors:  Cornelius Klöck; Chaitan Khosla
Journal:  Protein Sci       Date:  2012-11-09       Impact factor: 6.725

8.  Expression of Functional Recombinant Human Tissue Transglutaminase (TG2) Using the Bac-to-Bac Baculovirus Expression System.

Authors:  Yaghoub Yazdani; Shahram Azari; Hamid Reza Kalhor
Journal:  Adv Pharm Bull       Date:  2016-03-17

9.  Design of anti-inflammatory heparan sulfate to protect against acetaminophen-induced acute liver failure.

Authors:  Katelyn Arnold; Yongmei Xu; Erica M Sparkenbaugh; Miaomiao Li; Xiaorui Han; Xing Zhang; Ke Xia; Mark Piegore; Fuming Zhang; Xiaoxiao Zhang; Mike Henderson; Vijayakanth Pagadala; Guowei Su; Lisi Tan; Pyong Woo Park; Richard T Stravitz; Nigel S Key; Robert J Linhardt; Rafal Pawlinski; Ding Xu; Jian Liu
Journal:  Sci Transl Med       Date:  2020-03-18       Impact factor: 17.956

10.  Proteomic Profiling Reveals the Transglutaminase-2 Externalization Pathway in Kidneys after Unilateral Ureteric Obstruction.

Authors:  Giulia Furini; Nina Schroeder; Linghong Huang; David Boocock; Alessandra Scarpellini; Clare Coveney; Elisa Tonoli; Raghavendran Ramaswamy; Graham Ball; Claudia Verderio; Timothy S Johnson; Elisabetta A M Verderio
Journal:  J Am Soc Nephrol       Date:  2018-01-30       Impact factor: 10.121

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.